paired metastatic tumors, and 8 paired normal kidney samples by immunohistochemistry.
INTRODUCTION AND OBJECTIVES: T-LAK cell-originated protein kinase (TOPK), a serine/threonine protein kinase, was reported highly expressed in a variety of human tumors, and associated with poor prognosis of many kinds of human malignancies, but its activation mechanism is still uncovered. It is well known there is a bidirectional signals transduced between TOPK and ERK2, and ERK2 could phosphorylate TOPK at Thr9. The objective of the present study is to explore whether there is other site on TOPK that can be phosphorylated by ERK2, the function of the phosphorylation site was also be investigated.
METHODS: Potential phosphorylated serine/threonine sites of TOPK were predicted by NetPhos 2.0 software program. Peptide mapping assay was used to testify the phosphorylation site. Antiphospho-TOPK at S32 was prepared, the endogenous phosphorylation of TOPK at S32 was detected in renal cancer cells and tissues of renal cancer patients. In order to investigate the function of S32 site, S32 mutated TOPK (S32A) was transient transfected into 293T cells and stably transfected into JB6 or Caki-1 cells, the in vitro kinase assay was performed, the anchorage-independent growth ability and tumorigenesis of TOPK-S32A cells were compared. The ERK2 was knocked down from the TOPK highly expressed renal cancer cells, the level of phosphorylation TOPK (S32) and other downstream genes were detected.
RESULTS: We found that ERK2 directly bound with and phosphorylated TOPK at S32 in vitro. The phosphorylation was inhibited in cells expressing low levels of ERK2 or the cells that ERK2 was knocked down. When the S32 mutated TOPK was stably transfected into JB6, the anchorage-independent growth ability and tumorigenesis of the cells were suppressed compared with those of wild type TOPK (TOPK-WT) ex vivo and in vivo. The phosphorylation level of TOPK substrate, Histone H3 at Ser10 was also decreased dramatically ex vivo or in vivo. The phosphorylation level of TOPK was higher in high stage tissues of renal cancer than those in low stage ones.
CONCLUSIONS: Taken together, the phosphorylation of TOPK at S32 by ERK2 increases the activity of TOPK, and promotes the tumorigenesis of renal cancer. It may provide opportunities for TOPK based prognosis and targeted therapy for renal cancer patients.
Source of Funding: This project was supported by the national Natural Science Foundation of China (No.81572529).
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ERYTHROPOIETIN RECEPTOR MAY BECOME A TARGET FOR RENAL CELL CARCINOMA Teng Li*, Kan Gong, Pengjie Wu, Shengjie Liu, Xianghui Ning, Shuanghe Peng, Jiangyi Wang, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Drugs targeting the molecules downstairs VHL gene have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carcinoma (RCC). While the fact remains that despite a decade of established targeted therapy for RCC, the median survival of patients with metastatic RCC is still unsatisfying. Novel targeted therapies will have decisively improved the outlook for patients with renal cell cancer. In this study we evaluate the function of erythropoietin (Epo) and its receptor (EpoR) in RCC and whether it can be a target for RCC.
METHODS: RNA interference method was used to down regulate EpoR in RCC cell lines to investigate the function of Epo/EpoR pathway in human RCC cells. We also prepared polyclonal rabbit anti-EpoR antibody (EpoR Ab) by immunizing rabbits with the transmembrane domain polypeptide of EpoR, and tested the effect of the EpoR Ab for RCC cells in vitro and vivo.
RESULTS: Epo and EpoR co-express in RCC cell lines. Downregulation of EpoR expression in RCC cells by lentivirus-introduced siRNA resulted in inhibition of growth and invasiveness of RCC cells. The EpoR Ab could bound to RCC cells and inhibited the cancer cells proliferation in both vitro and vivo.
CONCLUSIONS: Our results suggested that Epo/EpoR pathway is involved in cell growth, invasion and survival in RCC cells. EpoR might be a new therapeutic target for renal cell carcinoma, and antibody against EpoR may become an effective agent for RCCs. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e791
Source (Mukai et al. Hum Cell, 2015) . MET is a high-affinity receptor tyrosine kinase of hepatocyte growth factor (HGF). HGF is secreted as an inactive singlechain precursor, which requires proteolytic activation for conversion to an active form. Matriptase is the most efficient known cellular activator of pro-HGF. Furthermore, activation of matriptase is regulated by HGF activator inhibitor (HAI). In this study, we employed a previously reported mouse model of bone metastasis (Strube et al. Clin Exp Metastasis, 2010) to clarify the significance of the matriptase-induced HGF/MET signaling axis in RCC bone metastasis.
METHODS: Luciferase-transfected 786-O cells were injected into the left cardiac ventricle of female nude mice (5 weeks old). After 6 weeks, we confirmed the formation of bone metastasis by whole-body bioluminescent imaging, and extracted specimens. Expression of matriptase, MET and HAI was analyzed by PCR, immunohistochemistry (IHC) and immunoblots. Phosphorylation of MET was also investigated. Based on the result, we produced HAI-2 (specific inhibitor of matriptase) stable knock down (KD) 786-O cells, and analyzed the difference of expression in each molecule, cell-migration assay and invasion assay.
RESULTS: Expression of matriptase was increased significantly in bone metastasis compared with parent cell line, and we confirmed increased phosphorylation of MET in bone metastasis. On the other hand, decreased expression of HAI-2 was observed in bone metastasis. Interestingly, increased matriptase expression was observed by HAI-2 KD in 786-O cells. In addition, invasive activity was increased significantly by knock down of HAI-2.
CONCLUSIONS: These results have suggested that matriptase contributes to the HGF-dependent MET activation in the pericellular microenvironment of bone metastasis in RCC. In addition, upregulation of matriptase and downregulation of HAI-2 may have important roles in their progression. METHODS: The human clear cell RCC line 786-O was stably transfected with the CaSR gene. Cell adhesion to endothelial cells and the extracellular matrix compounds fibronectin, collagen I and IV and a BSA control was determined after calcium treatment of the cells. Chemotactical cell migration was assessed using a Boyden migration chamber with calcium as chemotaxin. Cell proliferation after calcium treatment was quantified via BrdU incorporation. Signalling pathway activation after calcium treatment of the CaSR overexpressing cells was determined by a human phospho-kinase array and Western blot. Development of bone metastasis was evaluated in vivo by an intracardiac injection mouse model. RESULTS: Calcium treated overexpressing CaSR 768-O cells show an increased adhesion to endothelial cells and the extracellular matrix components fibronectin and collagen I, but not to collagen IV. The chemotactical cell migration and proliferation was also induced by calcium treatment. The signalling mediators SHC, AKT, ERK, p38a JNK, p90RSK, CREB were enhanced, SRC reduced active after calcium treatment of CaSR overexpressing cells, but not of control cells. These effects were abolished by the CaSR inhibitor NPS2143. Intracardiac injection of CaSR overexpressing 768-O cells showed an increased rate of bone metastasis in vivo compared to control cells detected by MRI and bioluminescence.
Source of
CONCLUSIONS: CaSR is an important component in the mechanism of bone metastasis in RCC in vitro and in vivo. Therefore, targeting CaSR may be beneficial in patients with advanced RCC with high CaSR expression. (RCC) has been shown to be associated with higher tumor stage irrespective of gender. Our previous data have also demonstrated that anti-androgen therapy results in tumor suppression in a xenograft model of AR-positive RCC. Therefore, we hypothesize that intratumoral steroidogenesis is a source of androgens in AR-positive RCC.
Source of Funding: Wilhelm Sander Foundation
METHODS: Using enzyme-linked immunosorbent assay (ELISA), testosterone (T) and dihydrotesterone (DHT) levels were measured in AR-positive human RCC cell lines and human female RCC tissues. Nude mice were also injected with an AR-positive RCC cell line, Caki2. When tumors became palpable, surgical castration was performed and anti-androgen therapies with enzalutamide and abiraterone acetate were initiated. ELISA was then used to measure serum and intratumoral androgen levels. Real-time polymerase chain reaction (RT-PCR) was used to measure the expression levels of key enzymes required for steroidogenesis in RCC cell lines, human RCC tissues, and xenografts.
RESULTS: AR-positive human RCC cell lines and tissues were found to have elevated levels of androgens compared to AR-negative controls (p<0.05), and both expressed key enzymes required for intracellular steroidogenesis. Intratumoral androgen concentrations also remained high following castration even with significant reduction in the serum levels of androgen in a xenograft model. Significant reduction of intratumoral androgen levels was also seen with androgen synthesis inhibitor (p<0.05). Moreover, increased expressions of key enzymes were seen following castration in the xenografts.
CONCLUSIONS: Intracrine androgen biosynthesis is a potential source of androgen in AR-positive RCC, and the androgen signaling axis is a potential target of intervention in AR-positive RCC.
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